CEO Stefan Oschmann is sticking to his previous forecast of annual peak sales of €500-700m for Mavenclad, excluding the US, and Merck has high hopes for another MS treatment, the BTK inhibitor evobrutinib, following promising Phase IIb data.
As it faces up to the sales decline of former flagship drug Rebif (interferon beta-1a), Merck KGAA is banking on new multiple sclerosis therapies to help it come through 2018 which, according to CEO Stefan Oschmann, will be a year of transition.
Speaking at the German group's annual press conference in Darmstadt on March 8, he described 2017 as "a year of...
While some are calling for Syncona to be wound up, the UK-based company believes many existing and new investors will back the creation of new private fund.
Antibody-drug conjugates are a major part of the oncology pipeline, and data presented at the American Society of Clinical Oncology meeting highlight the emergence of new technologies.
Lilly’s Mounjaro for diabetes rose from sixth to third position among the top-selling drugs in the first quarter of 2025, Rival Ozempic retained second position and Merck & Co’s immuno-oncology blockbuster Keytruda stayed far ahead.
